Atlas Trials

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT02588092 · TERMINATED

Trial details

NCT number
NCT02588092
Sponsor
ADC Therapeutics S.A.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Start date
2016-02-01
Primary completion
2018-08-29
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.